# US 2023/0055805 A1 · Toll-like receptor ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055805 A1
- Document ID: US20230055805A1
- Status: Published application
- Kind: A1
- Application number: 17/898,165
- Filed: 2022-08-29
- Published: 2023-02-23
- Earliest claimed: 2018-02-12
- Assignees: Inimmune Corporation
- Applicants: Inimmune Corporation
- Inventors: Helene Bazin-Lee; George Ettenger; Juhienah Khalaf; Kendal T. Ryter
- Web page: https://patentgrep.com/patent/US20230055805A1

## CPC

- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 39/12: Viral antigens
- A61K 39/35: Allergens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 17/04: Antipruritics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07H 15/04: attached to an oxygen atom of the saccharide radical
- C07H 15/12: attached to a nitrogen atom of the saccharide radical
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.

## Claims

### Claim at position 1

1-44. (canceled)

### Claim 45

A method of eliciting or enhancing, or modifying an immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I-a), or a pharmaceutically acceptable salt thereof,
wherein,
R2a, R2b, and R2c are each independently —CH(R10)(R11);
R3a is —OP(O)(OH)2, —OSO3H, or —OCH2P(O)(OH)2;
R3b is hydrogen or COOH, or an ester thereof;
R10, at each occurrence, is independently C8-14alkyl;
R11, at each occurrence, is independently —O—C(═O)C1-15alkyl, —O—C(═O)C1-15alkylene-Z2, —O—C2-16alkylene-Z2, or —O—C2-16alkyl; and
Z2, at each occurrence, is independently phenyl or a 5- to 6-membered heteroaryl, wherein Z2 is optionally substituted with 1-5 substituents independently selected from C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, —OC1-4haloalkyl, cyano, and halogen.

### Claim 46 (depends on 45)

The method of claim 45, wherein the immune response treats a cancer, an infectious disease, or an allergy in the subject.

### Claim 47 (depends on 45)

The method of claim 45, wherein the immune response treats an infectious disease in the subject.

### Claim 48 (depends on 47)

The method of claim 47, wherein the infectious disease is a bacterial, viral, fungal or prion infection.

### Claim 49 (depends on 45)

The method of claim 45, wherein the immune response treats an allergy in the subject.

### Claim at position 7

50-52. (canceled)

### Claim 53

A method of treating, preventing, or reducing the susceptibility to an allergy, an autoimmune condition, an infectious disease, cancer, ischemia reperfusion, sepsis, or ocular diseases such as macular degeneration, ocular hypertension, and ocular infection, in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I-a), or a pharmaceutically acceptable salt thereof,
wherein,
R2a, R2b, and R2c are each independently —CH(R10)(R11);
R3a is —OP(O)(OH)2, —OSO3H, or —OCH2P(O)(OH)2;
R3b is hydrogen or COOH, or an ester thereof;
R10, at each occurrence, is independently C8-14alkyl;
R11, at each occurrence, is independently —O—C(═O)C1-15alkyl, —O—C(═O)C1-15alkylene-Z2, —O—C2-16alkylene-Z2, or —O—C2-16alkyl; and
Z2, at each occurrence, is independently phenyl or a 5- to 6-membered heteroaryl, wherein Z2 is optionally substituted with 1-5 substituents independently selected from C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, —OC1-4haloalkyl, cyano, and halogen.

### Claim at position 9

54-55. (canceled)

### Claim 56 (depends on 45)

The method of claim 45, wherein the administering to the subject is by intramuscular, intradermal, subcutaneous, topical, intravenous or mucosal administration.

### Claim 57 (depends on 45)

The method of claim 45, further comprising administering to the subject a therapeutically effective amount of radiation therapy or an additional therapeutic agent selected from a chemotherapeutic agent and an immune modulatory agent such as an immune checkpoint inhibitor or tumor phagocytosis-inducing agent.

### Claim 58 (depends on 45)

The method of claim 45, further comprising administering to the subject an immunogenic quantity of an antigen.

### Claim 59 (depends on 45)

The method according to claim 45, wherein the method produces an IgA immune response.

### Claim 60 (depends on 45)

The method according to claim 45, wherein the method produces an IgG immune response.

### Claim 61

(canceled)

### Claim 62

A method of treating or preventing or reducing the severity of epileptic seizures comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I-a) or a pharmaceutically acceptable salt thereof,
wherein,
R2a, R2b, and R2c are each independently —CH(R10)(R11);
R3a is —OP(O)(OH)2, —OSO3H, or —OCH2P(O)(OH)2;
R3b is hydrogen or COOH, or an ester thereof;
R10, at each occurrence, is independently C8-14alkyl;
R11, at each occurrence, is independently —O—C(═O)C1-15alkyl, —O—C(═O)C1-15alkylene-Z2, —O—C2-16alkylene-Z2, or —O—C2-16alkyl; and
Z2, at each occurrence, is independently phenyl or a 5- to 6-membered heteroaryl, wherein Z2 is optionally substituted with 1-5 substituents independently selected from C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, —OC1-4haloalkyl, cyano, and halogen.

### Claim at position 17

63-64. (canceled)
